Correction to: Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2

Hirotooshi Watanabe¹ · Takeshi Morimoto² · Manabu Ogita³ · Satoru Suwa³ · Masahiro Natsuaki⁴ · Nobuhiro Suematsu⁵ · Yorihiro Koeda⁶ · Yoshihiro Morino⁶ · Akira Nikaido⁷ · Yoshiki Hata⁷ · Masayuki Doi⁸ · Kiyoshi Hibi⁹ · Kazuo Kimura⁹ · Shunsuke Yoda¹⁰ · Takeo Kaneko¹⁰ · Koji Nishida¹¹ · Kazuya Kawai¹¹ · Koji Yamaguchi¹² · Tetsuzo Wakatsuki¹² · Norimasa Tonoike¹³ · Masashi Yamamoto¹³ · Shogo Shimizu¹⁴ · Takao Shimohama¹⁵ · Junya Ako¹⁵ · Takeshi Kimura¹ on behalf of STOPDAPT-2 Investigators

Published online: 12 February 2021
© Japanese Association of Cardiovascular Intervention and Therapeutics 2021

Correction to:
Cardiovascular Intervention and Therapeutics
<https://doi.org/10.1007/s12928-020-00719-6>

In the original publication of the article, Fig. 4(B) and 4(C) were published incorrectly. The correct figures are given in this correction.

The original article can be found online at <https://doi.org/10.1007/s12928-020-00719-6>.

✉ Takeshi Kimura
taketaka@kuhp.kyoto-u.ac.jp

- ¹ Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
- ² Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan
- ³ Department of Cardiovascular Medicine, Juntendo University Shizuoka Hospital, Izunokuni, Japan
- ⁴ Department of Cardiovascular Medicine, Saga University, Saga, Japan
- ⁵ Department of Cardiovascular Medicine, Saiseikai Fukuoka General Hospital, Fukuoka, Japan
- ⁶ Division of Cardiology, Department of Internal Medicine, Memorial Heart Center, Iwate Medical University, Morioka, Japan
- ⁷ Department of Cardiology, Minamino Cardiovascular Hospital, Hachioji, Japan

- ⁸ Department of Cardiology, Kagawa Prefectural Central Hospital, Takamatsu, Japan
- ⁹ Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan
- ¹⁰ Department of Internal Medicine, Division of Cardiology, Shimonoseki City Hospital, Shimonoseki, Japan
- ¹¹ Department of Cardiology, Chikamori Hospital, Kochi, Japan
- ¹² Department of Cardiovascular Medicine, Tokushima University Hospital, Tokushima, Japan
- ¹³ Department of Cardiology, Kimitsu Chuo Hospital, Kisarazu, Japan
- ¹⁴ Department of Cardiology, Mashiko Hospital, Kawaguchi, Japan
- ¹⁵ Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagami-hara, Japan

Fig. 4 The effect of 1-month DAPT relative to 12-month DAPT stratified by CYP2C19 genotypes. Effects of 1-month versus 12-month DAPT for the primary and major secondary endpoints stratified by **a** three CYP2C19 genotypes (PM, IM, and EM), **b** PM/IM and EM (with or without CYP2C19*2 or *3 LOF allele), **c** with or without

CYP2C19*2 LOF allele, and **d** with or without CYP2C19*3 LOF allele. CI, confidential interval; DAPT, dual antiplatelet therapy; EM, extensive metabolizer; HR, hazard ratio; IM, intermediate metabolizer; LOF, loss-of-function; and PM, poor metabolizer